KR20250007528A - 5-피리딘-1h-인다졸계 화합물, 약학적 조성물 및 응용 - Google Patents

5-피리딘-1h-인다졸계 화합물, 약학적 조성물 및 응용 Download PDF

Info

Publication number
KR20250007528A
KR20250007528A KR1020247036196A KR20247036196A KR20250007528A KR 20250007528 A KR20250007528 A KR 20250007528A KR 1020247036196 A KR1020247036196 A KR 1020247036196A KR 20247036196 A KR20247036196 A KR 20247036196A KR 20250007528 A KR20250007528 A KR 20250007528A
Authority
KR
South Korea
Prior art keywords
acid
compound
dmso
esi
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247036196A
Other languages
English (en)
Korean (ko)
Inventor
즈위 리
진레이 비엔
티엔싱 후
마이 리우
지아싱 송
즈시아 치우
홍치엔 우
시 쉬
쥐보 왕
Original Assignee
차이나 파마슈티칼 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 차이나 파마슈티칼 유니버시티 filed Critical 차이나 파마슈티칼 유니버시티
Publication of KR20250007528A publication Critical patent/KR20250007528A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247036196A 2022-08-24 2022-11-22 5-피리딘-1h-인다졸계 화합물, 약학적 조성물 및 응용 Pending KR20250007528A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211018173.7A CN115353508B (zh) 2022-08-24 2022-08-24 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN202211018173.7 2022-08-24
PCT/CN2022/133423 WO2024040768A1 (zh) 2022-08-24 2022-11-22 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Publications (1)

Publication Number Publication Date
KR20250007528A true KR20250007528A (ko) 2025-01-14

Family

ID=84003747

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247036196A Pending KR20250007528A (ko) 2022-08-24 2022-11-22 5-피리딘-1h-인다졸계 화합물, 약학적 조성물 및 응용

Country Status (8)

Country Link
US (1) US20260070889A1 (https=)
JP (1) JP2025515926A (https=)
KR (1) KR20250007528A (https=)
CN (1) CN115353508B (https=)
AU (1) AU2022475622A1 (https=)
CA (1) CA3255205A1 (https=)
GB (1) GB2632571A (https=)
WO (1) WO2024040768A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115353508B (zh) * 2022-08-24 2023-07-21 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN115785071B (zh) * 2023-01-09 2024-01-26 中国药科大学 3-乙炔基-5-（1h-1,2,3-三唑-4-基）-1h-吲唑类化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
CA2819373A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
PH12017500997A1 (en) * 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2014137728A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN106032359B (zh) * 2015-03-09 2018-07-20 复旦大学 吲唑类化合物及其制备方法和用途
MX380092B (es) * 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
CN105958990B (zh) * 2016-05-24 2019-03-29 内蒙古包钢钢联股份有限公司 光电接近开关保护装置
WO2019241540A1 (en) * 2018-06-15 2019-12-19 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
US20230000842A1 (en) * 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
WO2022012058A1 (zh) * 2020-07-16 2022-01-20 江苏凯迪恩医药科技有限公司 稠环化合物及其中间体、制备方法和应用
CN115353508B (zh) * 2022-08-24 2023-07-21 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Also Published As

Publication number Publication date
GB2632571A (en) 2025-02-12
JP2025515926A (ja) 2025-05-20
CN115353508A (zh) 2022-11-18
WO2024040768A1 (zh) 2024-02-29
GB202415076D0 (en) 2024-11-27
CN115353508B (zh) 2023-07-21
US20260070889A1 (en) 2026-03-12
CA3255205A1 (en) 2025-03-27
AU2022475622A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
JP6861858B2 (ja) Ｓｓａｏ阻害剤
US5767283A (en) 7-Amino-1H-indoles
US5721246A (en) Heterobicyclic sulfonamide and sulfonic ester derivatives
JP6966423B2 (ja) 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
JP2010520162A (ja) ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
AU2004238521A1 (en) Isoquinoline derivatives and their use as GFAT inhibitors
CN112047931B (zh) FXIa凝血因子抑制剂、其药物组合物和用途
EA007715B1 (ru) Ингибиторы вирусной полимеразы
CN102918034A (zh) 多取代芳族化合物作为凝血酶的抑制剂
WO2014023083A1 (zh) PI3Kδ抑制剂
KR20070026357A (ko) 인돌 유도체, 및 키나제 억제제, 특히 ｉｋｋ2억제제로서의 그의 용도
CN116262736B (zh) 新型氧代吡啶类化合物及其制备方法和用途
KR20250007528A (ko) 5-피리딘-1h-인다졸계 화합물, 약학적 조성물 및 응용
CN114929690B (zh) 用于治疗心脏病的具有心肌细胞增殖活性的新型杂环衍生物
CN115703761A (zh) 作为wwp1抑制剂的化合物及其应用
EP2774919A1 (en) Novel sulfonamide TRPA1 receptor antagonists
EP2733144B1 (en) Novel compound having parp inhibitory activity
MX2007007023A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
CN115304583B (zh) 靶向抑制clk2的5-吡啶-1h-吲唑类化合物及其应用
CZ207794A3 (en) Indole compounds, process of their preparation, intermediates and pharmaceutical compositions based thereon
AU2003249067A1 (en) Furanthiazole derivatives as heparanase inhibitors
CN112010774B (zh) FXIa凝血因子抑制剂、其药物组合物和用途
CN117229259B (zh) 一种8-喹啉磺酰胺苯基咪唑类化合物及其应用
JP4861179B2 (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
CN118146197A (zh) 炔类化合物及其制备方法、药物组合物与应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902